[go: up one dir, main page]

WO2012051498A3 - Antibodies that bind amyloid oligomers - Google Patents

Antibodies that bind amyloid oligomers Download PDF

Info

Publication number
WO2012051498A3
WO2012051498A3 PCT/US2011/056293 US2011056293W WO2012051498A3 WO 2012051498 A3 WO2012051498 A3 WO 2012051498A3 US 2011056293 W US2011056293 W US 2011056293W WO 2012051498 A3 WO2012051498 A3 WO 2012051498A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
amyloid oligomers
bind amyloid
bind
oligomer
Prior art date
Application number
PCT/US2011/056293
Other languages
French (fr)
Other versions
WO2012051498A2 (en
Inventor
Rakez Kayed
Original Assignee
The Board Of Regents Of The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Regents Of The University Of Texas System filed Critical The Board Of Regents Of The University Of Texas System
Priority to CA2817973A priority Critical patent/CA2817973C/en
Priority to EP11833463.0A priority patent/EP2627357B1/en
Priority to AU2011315920A priority patent/AU2011315920B2/en
Publication of WO2012051498A2 publication Critical patent/WO2012051498A2/en
Publication of WO2012051498A3 publication Critical patent/WO2012051498A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Embodiments of the invention are directed to compositions and methods related to immunogenic compositions comprising the amino acid sequence of SEQ ID NO: l and amyloid oligomer specific antibodies that specifically bind an oligomer comprising such a peptide.
PCT/US2011/056293 2010-10-15 2011-10-14 Antibodies that bind amyloid oligomers WO2012051498A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2817973A CA2817973C (en) 2010-10-15 2011-10-14 Antibodies that bind amyloid oligomers
EP11833463.0A EP2627357B1 (en) 2010-10-15 2011-10-14 Antibodies that bind amyloid oligomers
AU2011315920A AU2011315920B2 (en) 2010-10-15 2011-10-14 Antibodies that bind amyloid oligomers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39368510P 2010-10-15 2010-10-15
US61/393,685 2010-10-15

Publications (2)

Publication Number Publication Date
WO2012051498A2 WO2012051498A2 (en) 2012-04-19
WO2012051498A3 true WO2012051498A3 (en) 2012-08-02

Family

ID=45938990

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/056293 WO2012051498A2 (en) 2010-10-15 2011-10-14 Antibodies that bind amyloid oligomers

Country Status (5)

Country Link
US (2) US9125846B2 (en)
EP (1) EP2627357B1 (en)
AU (1) AU2011315920B2 (en)
CA (1) CA2817973C (en)
WO (1) WO2012051498A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2906596B1 (en) 2012-10-12 2023-12-27 Arizona Board of Regents on behalf of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
EP3207057A2 (en) 2014-10-16 2017-08-23 F. Hoffmann-La Roche AG Anti-alpha-synuclein antibodies and methods of use
GB2541003A (en) * 2015-08-05 2017-02-08 Kran Life Sciences Llp Neurodegenerative disorders
AU2016353552B2 (en) 2015-11-09 2022-01-06 The University Of British Columbia N-terminal epitopes in Amyloid beta and conformationally-selective antibodies thereto
AU2016353553B2 (en) 2015-11-09 2022-01-20 The University Of British Columbia Amyloid beta epitopes and antibodies thereto
JP7448174B2 (en) 2015-11-09 2024-03-12 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア Amyloid beta middle region epitope and conformation-selective antibodies against it
EP3484919A4 (en) 2016-07-18 2020-03-04 The University of British Columbia ANTIBODIES AGAINST AMYLOID BETA
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
SG11201906947SA (en) 2017-02-17 2019-08-27 Bristol Myers Squibb Co Antibodies to alpha-synuclein and uses thereof
WO2019114804A1 (en) * 2017-12-13 2019-06-20 凯惠科技发展(上海)有限公司 Egfrviii antibody and conjugate, and preparation method and use thereof
AU2019304384A1 (en) 2018-07-17 2021-01-28 Jiangsu Hengrui Medicine Co., Ltd. Anti-abeta antibody, antigen-binding fragment thereof and application thereof
WO2022099298A1 (en) * 2020-11-06 2022-05-12 Musc Foundation For Research Development Antibodies for use in the detection and treatment of heart disease
WO2022119932A1 (en) * 2020-12-02 2022-06-09 Agilent Technologies, Inc. Anti-human cd10 antibodies for use in immunohistochemistry (ihc) protocols to diagnose cancer
TW202300517A (en) 2021-03-12 2023-01-01 美商美國禮來大藥廠 Anti-amyloid beta antibodies and uses thereof
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005643A1 (en) * 2002-02-26 2004-01-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Anti-human tenascin monoclonal antibody
WO2004024090A2 (en) * 2002-09-12 2004-03-25 The Regents Of The University Of California Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
US20040137421A1 (en) * 2001-01-31 2004-07-15 Tetsuyuki Kitamoto Method of screening prion disease infection factor
US7439041B2 (en) * 2003-08-13 2008-10-21 Novartis Vaccines And Diagnostics, Inc. Prion-specific peptide reagents
US20090258009A1 (en) * 2006-03-23 2009-10-15 Bioarctic Neuroscience Ab Protofibril selective antibodies and the use thereof
US20100209422A1 (en) * 2007-11-16 2010-08-19 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE153534T1 (en) 1990-04-27 1997-06-15 John Mcmichael METHOD AND COMPOSITION FOR TREATING CNS DISEASES CAUSED BY ABNORMAL BETA-AMYLOID PROTEIN
JPH07507044A (en) 1991-12-06 1995-08-03 マックス−プランク−ゲゼルシャフト　ツール　フェルデルング　デル　ヴィッセンシャフテン　エー．ヴェー． Novel tools for diagnosis and treatment of Alzheimer's disease
NZ251621A (en) 1992-03-26 1996-04-26 Microcarb Inc Polyclonal antibodies to shiga-like toxins
US6770278B1 (en) 1994-12-02 2004-08-03 Central Biomedia, Inc. Methods of making and using immunoglobulin (Ig) compositions
US5548066A (en) 1994-12-02 1996-08-20 Central Biomedia, Inc. Failure of passive transfer immune serum and method of making same
US6756361B1 (en) 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
FI982481A0 (en) * 1998-11-17 1998-11-17 Wallac Oy Immunoassay for the detection of infectious bovine spongiform encephalopathy
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
AT500379B8 (en) 2001-02-02 2009-08-15 Axon Neuroscience TAU PROTEINS
KR101150548B1 (en) 2003-12-22 2012-07-06 글락소 그룹 리미티드 Nogo-a neutralising immunoglobulins for treatment of neurological diseases
US20070218491A1 (en) 2006-02-08 2007-09-20 Oligomerix, Inc. Oligomerization of amyloid proteins
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
GB0611708D0 (en) * 2006-06-14 2006-07-26 Common Services Agency Novel antibodies against prion protein and uses thereof
US20080220449A1 (en) 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
WO2011038575A1 (en) * 2009-09-30 2011-04-07 Glaxo Wellcome Manufacturing Pte Ltd Novel antibody treatment

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040137421A1 (en) * 2001-01-31 2004-07-15 Tetsuyuki Kitamoto Method of screening prion disease infection factor
US20040005643A1 (en) * 2002-02-26 2004-01-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Anti-human tenascin monoclonal antibody
WO2004024090A2 (en) * 2002-09-12 2004-03-25 The Regents Of The University Of California Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
US7439041B2 (en) * 2003-08-13 2008-10-21 Novartis Vaccines And Diagnostics, Inc. Prion-specific peptide reagents
US20090258009A1 (en) * 2006-03-23 2009-10-15 Bioarctic Neuroscience Ab Protofibril selective antibodies and the use thereof
US20100209422A1 (en) * 2007-11-16 2010-08-19 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JONES ET AL.: "The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling?", DEVELOPMENT DYNAMICS, vol. 218, 2000, pages 235 - 259, XP002250835, DOI: doi:10.1002/(SICI)1097-0177(200006)218:2<235::AID-DVDY2>3.0.CO;2-G *
See also references of EP2627357A4 *

Also Published As

Publication number Publication date
WO2012051498A2 (en) 2012-04-19
US9125846B2 (en) 2015-09-08
AU2011315920A1 (en) 2013-06-06
US20120148591A1 (en) 2012-06-14
EP2627357A4 (en) 2014-03-19
CA2817973C (en) 2019-06-25
US9895429B2 (en) 2018-02-20
EP2627357A2 (en) 2013-08-21
CA2817973A1 (en) 2012-04-19
US20150322143A1 (en) 2015-11-12
AU2011315920B2 (en) 2016-04-28
EP2627357B1 (en) 2017-05-03

Similar Documents

Publication Publication Date Title
WO2012051498A3 (en) Antibodies that bind amyloid oligomers
UA118167C2 (en) Peptides and their use
CL2013001124A1 (en) Isolated antibody or a protein comprising an antigen binding portion of an antibody directed against a cd40 polypeptide; pharmaceutical composition comprising said antibody; nucleic acid encoding the antibody; cloning vector; antibody production process.
WO2010129895A3 (en) Cd133 epitopes
MX348071B (en) Fc variants.
IN2014KN01713A (en)
IN2014KN01714A (en)
IN2014KN01716A (en)
WO2013059885A3 (en) Polypeptide constructs and uses thereof
WO2012088461A3 (en) Linker peptides and polypeptides comprising same
RU2016146198A (en) THERAPEUTIC DLL4-BINDING PROTEINS
WO2011163637A3 (en) Protein transduction domains mimics
UA111820C2 (en) MODIFIED BINDING PROTEIN INHIBITING VEGF-A-RECEPTOR INTERACTION
WO2010139736A3 (en) Recombinant production of peptides
WO2013000922A9 (en) Ccr2 antagonist peptides
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
WO2012047732A3 (en) Antibody compositions and methods of use
WO2014090905A8 (en) Modified coiled coil type proteins having improved properties
WO2012114125A3 (en) Treatment and prevention of malaria
WO2012091564A3 (en) A cross linking polypeptide comprising an hexameric single chain antibody binding mhc-mage complex that induces apoptosis
AR128395A2 (en) NOVEL PEPTIDES ABLE TO INDUCE THE FORMATION OF ANTIBODIES AGAINST PCSK9
JP2010265269A5 (en)
EA201492068A1 (en) PEPTID HYDROCHLORIDE SALT AND ITS APPLICATION IN COMBINATION WITH OTHER PEPTIDES IN IMMUNOTHERAPY
PH12015501033A1 (en) Peptides
WO2012027555A3 (en) Glycated cd59 peptides, their preparation, and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11833463

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2817973

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2011833463

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011833463

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011315920

Country of ref document: AU

Date of ref document: 20111014

Kind code of ref document: A